key: cord-0937542-dnyfh9um authors: Jagiasi, Bharat; Nasa, Prashant; Chanchalani, Gunjan; Ahmed, Ahsan; AK, Ajith Kumar; Sodhi, Kanwalpreet; Mangal, Kishore; Singh, Manoj K.; Gupta, Nitesh; Bidkar, Prasanna U.; Tyagi, Ranvir S.; Khanikar, Reshu G.; Tripathy, Swagata; Khanzode, Swapna; Subba Reddy, Kesavarapu; Saigal, Saurabh; Sivakumar, Vijay Anand; Javeri, Yash; Tekwani, Seema S. title: Variation in therapeutic strategies for the management of severe COVID‐19 in India: A nationwide cross‐sectional survey date: 2021-07-18 journal: Int J Clin Pract DOI: 10.1111/ijcp.14574 sha: 6e37472f3fd92d71dc91adb24b5e6c7ab9b5db1f doc_id: 937542 cord_uid: dnyfh9um AIM: During the pandemic of coronavirus disease 2019 (COVID‐19), the physicians are using various off‐label therapeutics to manage COVID‐19. We undertook a cross‐sectional survey to study the current variation in therapeutic strategies for managing severe COVID‐19 in India. METHODS: From January 4 to January 18, 2021, an online cross‐sectional survey was conducted among physicians involved in the management of severe COVID‐19. The survey had three sections: 1. Antiviral agents, 2. Immunomodulators, and 3. Adjuvant therapies. RESULTS: 1055 respondents (from 24 states and five union territories), of which 64.2% were consultants, 54.3% working in private hospitals, and 39.1% were from critical care medicine completed the survey. Remdesivir (95.2%), antithrombotics (94.2%), corticosteroids (90.3%), vitamins (89.7%) and empirical antibiotics (85.6%) were the commonly used therapeutics. Ivermectin (33%), convalescent plasma (28.6%) and favipiravir (17.6%) were other antiviral agents used. Methylprednisolone (50.2%) and dexamethasone (44.1%) were preferred corticosteroids and at a dose equivalent of 8 mg of dexamethasone phosphate (70.2%). There was significant variation among physicians from different medical specialities in the use of favipiravir, corticosteroids, empirical antibiotics and vitamins. CONCLUSION: There is a considerable variation in the physicians’ choice of therapeutic strategies for the management of severe COVID‐19 in India, as compared with the available evidence. The pandemic of coronavirus disease 2019 (COVID-19) had a significant impact on the healthcare systems globally and more so in third world countries, such as India. 1 February 2021). However, the mortality is lower, with a patient fatality rate of 1.15% compared with 2.1% worldwide. 2 There has been some debate on the low patient fatality rate, and it depends on various factors including the average age of the population, patient reporting and testing strategies. [3] [4] [5] More than 80% of the patients with COVID-19 have mild to moderate symptoms and may not require hospitalisation. However, 15%-20% of patients may develop severe COVID-19, which is defined as the presence of pneumonia and clinical signs of respiratory distress, or peripheral oxygen saturation (SpO 2 ) <90% on room air, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Pao 2 :Fio 2 ) of <300 mm Hg, or >50% lung infiltrates. 6 Patients usually develop severe COVID-19 one week after the onset of symptoms and can deteriorate rapidly, requiring hospital and intensive care unit (ICU) admissions. 7 The reported mortality in severe COVID-19 is 34%-50%, with a decline in the last few months. [8] [9] [10] The mortality in severe COVID-19 is dependent on various factors such as age, male sex, organ dysfunction, the severity of respiratory failure (lower PaO2/Fio2 ratio), and the requirement of invasive mechanical ventilation. [9] [10] [11] The rapid growth of COVID-19 pandemic propelled off-label July 2020. 12 There has been significant research on the various treatment options for moderate-severe COVID-19 in the last few months. The landmark RECOVERY trial has revealed that dexamethasone can reduce significant mortality in patients on oxygen support or invasive mechanical ventilation while conferring no benefit in those not requiring oxygen. 13 In the absence of revision in the guidelines, there is an expected variation in the pharmacological management of COVID-19. We undertook a nationwide cross-sectional survey over two weeks in January 2021 to study the variation in the therapeutic strategies of severe COVID-19 in India. An online cross-sectional survey on the pharmacological treatment of severe COVID-19 using "Google forms" was conducted from 4 January to 18 January 2021. Eighteen physicians from corticosteroids (90.3%), vitamins (89.7%) and empirical antibiotics (85.6%) were the commonly used therapeutics. Ivermectin (33%), convalescent plasma (28.6%) and favipiravir (17.6%) were other antiviral agents used. Methylprednisolone (50.2%) and dexamethasone (44.1%) were preferred corticosteroids and at a dose equivalent of 8 mg of dexamethasone phosphate (70.2%). There was significant variation among physicians from different medical specialities in the use of favipiravir, corticosteroids, empirical antibiotics and vitamins. Conclusion: There is a considerable variation in the physicians' choice of therapeutic strategies for the management of severe COVID-19 in India, as compared with the available evidence. • The common therapeutic agents in the management of severe COVID-19 in India, include remdesivir, antithrombotics, corticosteroids, vitamins and empirical antibiotics. • There is a significant variation among physicians of different medical specialities in the use of favipiravir, corticosteroids, empirical antibiotics and vitamins for severe COVID-19. • There is a considerable variation in the physicians' choice of therapeutic strategies for severe COVID-19 in India as compared with the available evidence. Critical Care Medicine, Anaesthesiology, Pulmonary Medicine and Internal Medicine involved in managing severe COVID-19 and representing prominent states were invited into the steering group. We searched "Google Scholar" and "PubMed" electronic databases using search terms "therapeutics," "pharmacological treatment," "management," AND "COVID-19," "SARS-CoV-2." We reviewed all English language, published research, including national guidance from MOHFW, India, World Health Organisation (WHO) on adult humans with COVID-19, published during 2020. With the help of a heterogenous steering group, we also included other off-label medications currently being used in India. The survey was then prepared using several qualitative or quantitative clinical practice points on the pharmacological treatment of severe COVID-19. A dry run of the survey was conducted among the steering group for any typographical mistakes and feedback. The survey was circulated to physicians through e-mail and social media channels and consent was taken from all respondents. A concerted effort was taken to invoke participation from all the states, public and private hospitals, and across all medical specialties involved in managing Over two weeks, 1063 complete responses were received, and1055 were finally analysed (responses from outside of India were removed). The respondents from 24 (85.7%) Indian states and five (62.5%) union territories participated in the survey, representing approximately 99.3% of Indian population ( Figure 1 ). 64.2% of the respondents were consultants or senior consultants, 54.3% working in private hospitals and 31.9% in medical college. The top three medical specialities were critical care medicine (39.1%), anaesthesia (26.4%) and pulmonary medicine (11%) (Appendix 2, Figure 1 ). Remdesivir (95.2%) and corticosteroids (90.3%), each for 5-10 days, were the most common therapeutics chosen by respondents. (Figure 2 ) The majority of the responders were using empirical antibiotics (85.6%), vitamins (89.7%) and antithrombotics (94.2%) as adjuvant therapies in severe COVID-19. 71.6% used remdesivir for severe COVID-19, while 65.2% and 53.6% for moderate and critical COVID-19, respectively (Tables 1 and 2 ). The other primary antiviral agent being used included ivermectin (33%), convalescent plasma (28.6%) and favipiravir (17.6%). 31.5% and 47% of respondents respectively, used ivermectin and convalescent plasma irrespective of the disease severity, while 80% used favipiravir for moderate illness. Tocilizumab is the other immunomodulator used by 40% of respondents, and even con- The arduous clinical work during pandemic and rapidly evolving evidence made it difficult for physicians to keep abreast of the latest research. The deluge of information through print or social media, the pre-peer review release of the research, and political interference in the science have further perplexed physicians. Researchers globally have made substantial progress in the last few months to understand the pathophysiology and explore various therapeutic options for severe COVID-19. [13] [14] [15] [16] We undertook this survey in January 2021, after the first wave of the pandemic of COVID-19 started receding in India, to study the variation in therapeutic strategies. Remdesivir, corticosteroids and prophylactic antithrombotics were the most common therapeutic agents used by the physicians to manage severe COVID-19. There was considerable use of empirical antibiotics and vitamins by the physicians. There was also significant variation among physicians based on their working specialities in the use of therapeutics such as favipiravir, corticosteroids, empirical antibiotics, and vitamins to manage COVID-19. Similarly, there was a significantly higher use of favipiravir in critical COVID-19 among physicians from non-frontline medical specialities (9.0%). The use of favipiravir is discrepant with MOHFW guidelines on clinical management protocol for COVID-19 and available evidence. 12, 19 Two-third of the respondents who agreed to use convalescent plasma in severe COVID-19 used a single session or dose. The largest RCT on convalescent plasma from India in non-critical COVID-19 F I G U R E 1 Geographical The majority (90.3%) of the respondents agreed to the use of corticosteroids in severe COVID-19. There was, however, a divide, ing respiratory or cardiovascular organ support in ICU. 25, 26 19.8% of the respondents, especially consultants, were using ulinastatin (a urinary trypsin inhibitor) in severe COVID-19. 8.2% of respondents also agreed to use sepsivac (heat-killed Mycobacterium W), and 8.7% thymosin (purified peptide from bovine thymic tissues) as immunomodulators for severe COVID-19. There are no prospective studies available on these therapeutics in COVID-19, and some of them are undergoing trials at present in India. 27 tests excluded bacterial co-infection. 29 The authors did not recommend any empirical antibiotic regimen and advised to use community or hospital-acquired pneumonia guidelines while starting antibiotics and using local antimicrobial surveillance. 29 Recently, the RECOVERY trial found no role of azithromycin in the treatment of hospitalised COVID-19 patients. 30 The prepublication release from the PRINCIPAL trial using azithromycin or doxycycline for 14 days showed no significant benefit in time to recovery or hospitalisation. 31 higher number of physicians from public or medical college-hospitals in severe COVID-19. In a retrospective study of 412 patients, aspirin use was associated with reduced use of invasive mechanical ventilation, ICU admission and hospital mortality. 34 However, this association has not been proved in any prospective study so far and cannot be recommended as a standard therapy. NIH recommends the continuation of antiplatelets in patients on chronic antiplatelet therapy before COVID-19. 35 The strength of this study is its widespread representation from most states and union territories, public or private hospitals, and physicians from different rank or medicine specialities. Secondly, the large number (over 1000) of participation in a short time frame of two weeks helped capture practice variation over a wide range of therapeutic strategies. Thirdly, the study was con- There are few limitations in this study. The data on the age and gender of responders was not collected. However, the decision making of physicians is closely linked to their designation in the hospital rather than age. The inherent limitations of a crosssectional survey, such as respondents recall bias, a measure of point prevalence and failure to follow the trend is also applica- Remdesivir, corticosteroids, and prophylactic antithrombotics are the most used therapeutic strategies in managing severe COVID-19 in India. There is considerable use of empirical antibiotics and therapeutic vitamins by physicians in severe COVID-19. There is variation among physicians on the use of pharmaceutical agents in comparison to available evidence. Periodical update on the national guidelines is required to educate physicians on the rapidly evolving evidence. We acknowledge the contribution of Rohit Ravindra Dussane in the statistical analysis of the results. All authors declare no conflict of interest related to this article. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of privacy or ethical restrictions. Prashant Nasa https://orcid.org/0000-0003-1948-4060 Prasanna U. Bidkar https://orcid.org/0000-0002-4497-6772 COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India An interactive web-based dashboard to track COVID-19 in real time Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: meta-analysis and sensitivity analysis Is India missing COVID-19 deaths? Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention Severe covid-19 Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. a meta-analysis Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy Ministry of Health and Family Welfare Directorate General of Health Services. Clinical management protocol: COVID-19 Dexamethasone in hospitalized patients with covid-19 -preliminary report Clinical management of COVID-19. Interim guidance COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City Remdesivir for the treatment of covid-19 -final report Repurposed antiviral drugs for covid-19 -Interim WHO Solidarity trial results The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19 Role of favipiravir in the treatment of COVID-19 Convalescent plasma in the management of moderate covid-19 in adults in India:open label phase II multicentre randomised controlled trial (PLACID Trial) Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia Covid-19: Arthritis drugs improve survival in intensive care patients, shows study Snapshot of COVID-19 related clinical trials in India Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Recommendations for antibacterial therapy in adults with COVID-19 -an evidence based guideline Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19 Treatment Guidelines Vitamin D and Covid-19: an update on evidence and potential therapeutic implications Aspirin use is associated with decreased mechanical ventilation, ICU admission, and inhospital mortality in hospitalized patients with COVID-19 Antithrombotic Therapy in Patients with COVID-19 Additional Supporting Information may be found online in the